শুক্রবার, ২৬ এপ্রিল ২০২৪, ১৩ বৈশাখ ১৪৩১

Groundbreaking success in COVID-19 treatment

Groundbreaking success in COVID-19 treatment

For the first time in the country, Eskayef Pharmaceuticals, a leading pharmaceutical company, has produced Remdesivir injection to help treat the hospitalised patients suffering from the deadly COVID-19.

The Remdesivir injection will be supplied to the dedicated hospitals treating novel Coronavirous-infected patients with effect from Sunday next (May 10) by the Eskayef Pharmaceuticals, said Director (Marketing and Sales) Dr. Mohammad Mujahidul Islam on Friday.

“We have produced the important drug successfully today and taken required preparations to supply it to the hospitals concerned,” he informed.

“Price of a vial of the Remdesivir injection has been fixed at Tk 5,500,” he disclosed.

“After meeting the demand in our country, we will focus on the export market for the Remdesivir injection after obtaining prior permission from the drug administration,” he added.

However, Dr.

Mujahidul informed that they would produce the drug in phases as per the requirement of the drugs in the hospitals concerned.

The US-based company Gilead Sciences Inc has created the drug for the treatment of COVID-19 and the US Food and Drug Administration (FDA) has already approved Remdesivir last week.

The drug administration in Japan did also okay the drug on May 7 to use it for coronavirus patients.

Market sources said Eskayef is the first drug manufacturing company in the world to successfully manufacture generic Remdesivir.

The authorities concerned have already given permission to six local pharmaceuticals companies — Beximco, Eskayef (SK-F), Incepta, Beacon, Healthcare and Square ­– to produce the antiviral drug Remdesivir.

For the first time in the country, Eskayef Pharmaceuticals, a leading pharmaceutical company, has produced Remdesivir injection to help treat the hospitalised patients suffering from the deadly COVID-19.

The Remdesivir injection will be supplied to the dedicated hospitals treating novel Coronavirous-infected patients with effect from Sunday next (May 10) by the Eskayef Pharmaceuticals, said Director (Marketing and Sales) Dr. Mohammad Mujahidul Islam on Friday.

“We have produced the important drug successfully today and taken required preparations to supply it to the hospitals concerned,” he informed.

“Price of a vial of the Remdesivir injection has been fixed at Tk 5,500,” he disclosed.

“After meeting the demand in our country, we will focus on the export market for the Remdesivir injection after obtaining prior permission from the drug administration,” he added.

However, Dr. Mujahidul informed that they would produce the drug in phases as per the requirement of the drugs in the hospitals concerned.

The US-based company Gilead Sciences Inc has created the drug for the treatment of COVID-19 and the US Food and Drug Administration (FDA) has already approved Remdesivir last week.

The drug administration in Japan did also okay the drug on May 7 to use it for coronavirus patients.

Market sources said Eskayef is the first drug manufacturing company in the world to successfully manufacture generic Remdesivir.

The authorities concerned have already given permission to six local pharmaceuticals companies — Beximco, Eskayef (SK-F), Incepta, Beacon, Healthcare and Square ­– to produce the antiviral drug Remdesivir.

আলোকিত সিরাজগঞ্জ

শিরোনাম:

স্টেশনে যাত্রীরাই কাটতে পারবেন ট্রেনের টিকিট
এপ্রিলের ১৯ দিনে রেমিট্যান্স এসেছে ১২৮ কোটি ডলার
পুলিশকে সাহায্য করবে ক্রাইম জিপিটি!
পুনর্মিলনী অনুষ্ঠানে স্কুলজীবনের মজার স্মৃতিতে প্রাক্তন শিক্ষার্থীরা
কাজিপুরে ভার্মি কম্পোস্ট সার বানিজ্যিকভাবে উৎপাদন শুরু
১৪ কিলোমিটার আলপনা বিশ্বরেকর্ডের আশায়
আলো ছড়াচ্ছে কুষ্টিয়ার বয়স্ক বিদ্যালয়
মেয়েদের স্কুলের বেতন না দিয়ে ধোনিদের খেলা দেখলেন তিনি
‘ডিজিটাল ডিটক্স’ কী? কীভাবে করবেন?
তাপপ্রবাহ বাড়বে, পহেলা বৈশাখে তাপমাত্রা উঠতে পারে ৪০ ডিগ্রিতে
নেইমারের বাবার দেনা পরিশোধ করলেন আলভেজ
দেশবাসীকে বাংলা নববর্ষের শুভেচ্ছা প্রধানমন্ত্রীর